Kura Oncology, Inc. Operating Income Loss

• Kura Oncology, Inc. showed a decrease of -57.2% in Operating Income Loss from 2024 to 2025.
• This data is from Kura Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
• XBRL data for this metric is available from 2010 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2010 to 2025), Kura Oncology, Inc.'s Operating Income Loss has declined by 1,480,376.9%.
• Historical annual values: Fiscal year 2025: -$303.63 million | Fiscal year 2024: -$193.20 million | Fiscal year 2023: -$165.80 million | Fiscal year 2022: -$139.87 million | Fiscal year 2014: -$23.9 thousand | Fiscal year 2013: -$22.7 thousand | Fiscal year 2012: -$22.3 thousand | Fiscal year 2011: -$23.4 thousand | Fiscal year 2010: -$20.5 thousand.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026